Top Japanese Companies To Buy Right Now

SoftBank can check off one more item on its to-do list in its mission to acquire Sprint Nextel (NYSE: S  ) . On Thursday, the Japanese telecom announced the Securities and Exchange Commission gave its OK for Sprint to begin mailing proxy materials to shareholders regarding the upcoming vote on the transaction.

That vote will be held June 12 at a special shareholders' meeting, and it goes without saying (but I am saying it anyway) that SoftBank will be encouraging Sprint investors to vote for the proposal.

But the SEC thumbs up was just a small barrier compared to what SoftBank will have to scramble over before it can close on the deal.

DISH Network (NASDAQ: DISH  ) announced two weeks ago that it, too, wanted to buy Sprint, offering $25.5 billion compared to the $20.1 billion SoftBank bid. SoftBank's challenge will be to convince the Sprint shareholders that the DISH offer is less than what it seems.

That process began earlier this week when SoftBank CEO Masayoshi Son held a press conference in Tokyo questioning the veracity of DISH's claim that its offer would be worth $7 a share. "I would say the number is wrong. Totally wrong. It is incomplete and illusory," Son said.

Best Cheapest Companies To Watch For 2015: DSW Inc (DSW)

DSW Inc. (DSW), incorporated on January 20, 1969, is a United States branded footwear and accessories specialty retailer operating 326 shoe stores in 40 states as of January 28, 2012, and dsw.com. DSW has two segments: the DSW segment, which includes the DSW stores and dsw.com sales channels, and the leased business division segment. As of January 28, 2012, it operated 326 DSW stores, dsw.com and leased departments in 261 Stein Mart stores, 74 Gordmans stores and one Frugal Fannie�� store. During the fiscal year ended January 28, 2012 (fiscal 2011), DSW opened 17DSW stores and closed two DSW stores. On May 26, 2011, Retail Ventures, Inc. (RVI) merged with and into DSW MS LLC (Merger Sub), with Merger Sub surviving the Merger and continuing as a wholly owned subsidiary of DSW. In March 2012, the Company announced the opening of its store on 34th Street in Manhattan. In September 2013, DSW Inc announced the opening of a new store in Eatontown, NJ. In October 2013, DSW Inc announced the opening of two new stores in New York City. In October 2013, DSW Inc announced the opening of a new store in Greenville, SC.

The Company offers an assortment of brand name and designer dress, casual and athletic footwear for women and men, as well as accessories through its DSW stores and dsw.com. It also offers kids' shoes exclusively on dsw.com. The Company leases stores, distribution and fulfillment centers and office facilities under various arrangements with related and unrelated parties. DSW also operates leased departments for three retailers in its leased business division segment. As of January 28, 2012, DSW supplied merchandise to 261 Stein Mart stores, 74 Gordmans stores and one Frugal Fannie�� store. During fiscal 2011, DSW added 20 leased departments and ceased operations in 36 leased departments.

Advisors' Opinion:

• [By Teresa Rivas]

  DSW (DSW) was up 2% in after-hours trading, on the company�� increased full year earnings guidance and two-for-one stock split.

  The shoe retailer said that it now expects to earn between $3.60 and $3.80 a share, up from a previous range of $3.40 and $3.60 a share and well ahead of the $3.58 a share analysts were expecting.

  It also announced that it will hold a special shareholder meeting to seek approval for a 2-for-1 stock split of its common shares.

  For the recently ended second quarter, DSW said sales totaled $558 million, below the $568.5 million consensus estimate. Same-store sales rose 4.3%.

• [By Laura Brodbeck]

  Earnings Expected: From�Barnes & Noble, Inc. (NYSE: BKS), DSW Inc. (NYSE: DSW), Tiffany & Co., Hormel Foods Corporation (NYSE: HRL), TiVo Inc., Analog Devices, Inc. (NASDAQ: ADI), Hewlett-Packard Company.

• [By Paul Ausick]

  Big earnings movers: Tiffany & Co. (NYSE: TIF) reported better-than-expected earnings and revenues and raised its guidance slightly, but even posting a new 52-week high early could hold the stock from dropping about 1.3% today. Brown Shoe Co. Inc. (NYSE: BWS) also posted good earnings, but followed with slightly lower EPS guidance and the stock lost about 9%, trading around $21.60 in a 52-week range of $13.68 to $24.78. Another footwear maker, DSW Inc. (NYSE: DSW) put up good results and raised its guidance as well, sending shares up more than 9% to a new 52-week high of $88.73 in the mid-morning.

• [By Jake L'Ecuyer]

  DSW (NYSE: DSW) shares tumbled 5.45 percent to $44.65 after the company reported weak Q3 revenue.

  21Vianet Group (NASDAQ: VNET) was down, falling 7.66 percent to $16.99 after the company reported its unaudited Q3 financial results. Pacific Crest downgraded the stock from Outperform to Sector Perform.

Top Japanese Companies To Buy Right Now: S&P 500/Barra Value(SU)

Suncor Energy Inc., together with its subsidiaries, operates as an integrated energy company. The company involves in the development of petroleum resource basins in Canada's Athabasca oil sands; acquisition, exploration, development, production, and marketing of crude oil and natural gas in Canada and internationally; transportation and refining of crude oil; and marketing of petroleum and petrochemical products primarily in Canada. Its Oil Sands segment produces bitumen recovered from oil sands through mining and in-situ technology, and upgrades it into refinery feedstock, diesel fuel, and by-products. This segment?s products include gasoline and distillates. The company?s Natural Gas segment acquires, explores, develops, and produces natural gas, natural gas liquids, oil, and by-products from reserves located primarily in western Canada, the Northwest Territories, Alaska, and the Arctic Islands. Its International and Offshore segment engages in the exploration and pro duction of oil and gas in offshore Newfoundland and Labrador, in the North Sea, and in Libya and Syria. The company?s Refining and Marketing segment refines crude oil at Suncor's refineries in Edmonton, Alberta; Montreal, Quebec; and Sarnia, Ontario in Canada, as well as in Commerce City, Colorado into a range of petroleum and petrochemical products for sale to retail, commercial, and industrial customers. It also transports crude oil through pipelines in eastern and western Canada, as well as through wholly-owned pipelines in Wyoming and Colorado; and produces specialty lubricants and waxes. In addition, this segment operates retail sites in Canada under the Petro-Canada brand; and in Colorado under Phillips 66 and Shell brands. Suncor Energy Inc. also engages in third-party energy trading activities. The company was formerly known as Suncor Inc. and changed its name to Suncor Energy Inc. in April 1997. Suncor Energy Inc. was founded in 1953 and is headquartered in Calgary , Canada.

Advisors' Opinion:

• [By Achilles Research]

  Marathon Oil has been doing well for shareholders with the second best performance in the peer group. Anadarko Petroleum (APC), which I have rated as a Sell recently because the share price has run away from its fundamentals, has returned 186% over five years. Marathon Oil achieved 124%, Occidental Petroleum (OXY) 105%, Suncor Energy (SU) 63%, Apache Corp. (APA) 20% and Devon Energy (DVN) 14%. As a value investor with a contrarian tilt I naturally look at underperformers because they often offer the best risk/reward ratio and asymmetric pay-off profiles. I also just recently added to my positions in Devon Energy and Apache Corp. as they are just too cheap to ignore (thesis here and here). Apache was extraordinarily hit on overblown fears of potential oil production interruptions in Egypt and corresponding asset sales.

Top Japanese Companies To Buy Right Now: Pharmacyclics Inc (PCYC)

Pharmacyclics, Inc., incorporated on April 19, 1991, is a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. The Company's clinical development and product candidates are small-molecule enzyme inhibitors designed to target biochemical pathways involved in human diseases. As of June 30, 2011, it had three drug candidates under clinical development and a number of preclinical lead molecules. This includes an inhibitor of Bruton�� tyrosine kinase (Btk) (PCI-32765) in Phase II studies in hematologic malignancies; a Btk inhibitor lead optimization program targeting autoimmune indications, an inhibitor of Factor VIIa (PCI-27483) in a Phase II clinical trial in pancreatic cancer, and a histone deacetylase (HDAC) inhibitor (PCI-24781) in Phase I and II clinical trials in solid tumors and hematological malignancies as of June 30, 2012.

As of June 30, 2012, the Company developed ibrutinib, which has demonstrated clinical activity and tolerability in Phase I and Phase II clinical trials in a variety of B-cell malignancies, including chronic lymphocytic leukemia (CLL) and a number of non-Hodgkin�� lymphoma (NHL) subtypes. CLL, mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse B-cell lymphoma (DLBCL) and multiple myeloma (MM) are specific indications of its current or planned Phase Ib/II and Phase III development program. had development programs for B-cell malignancies and autoimmune diseases. For malignant indications it has developed PCI-32765, which has demonstrated clinical activity and tolerability in Phase I and Phase II clinical trials in a range of B-cell malignancies, including chronic lymphocytic leukemia (CLL) and a number of non-Hodgkin�� lymphoma (NHL) subtypes. CLL, mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse large B cell lymphoma (DLBCL) and multiple myeloma (MM) are specific indications of its Phase II development. It has developed an assay! to measure occupancy of Btk in PBMCs using a cell-permeable fluorescently-labeled derivative of PCI-32765.

Factor VII is an enzyme that becomes activated (FVIIa) by binding to the cell surface protein tissue factor (TF), a protein found in the body that helps to trigger the process of blood clotting in response to injury. TF is over expressed in many cancers including gastric, breast, colon, lung, prostate, ovarian and pancreatic cancers. In these tumors, the FVIIa/TF complex induces intracellular signaling pathways by activating protease activated receptor 2 (PAR-2), another cell-surface protein. This in turn increases the expression of interleukin-8 (IL-8), a protein produced by white blood cells and other immune cells in response to pathogenic stimulation, and vascular endothelial growth factor (VEGF), a signal protein produced by cells that stimulate the growth of blood vessels. Both proteins play an important role in tumor growth and metastases as well as angiogenesis (growth of new blood vessels). FVIIa/TF complex also initiates the coagulation (a process by which blood forms clots) processes implicated in the high incidence of thromboembolic (the process by which the blood clots within a blood vessel) complications seen in patients with TF-expressing cancers. Thromboembolic events are a cause of death in patients with cancer and anticoagulant treatment has been shown to improve survival in a variety of cancers (Klerk et al. JCO. 2005).

PCI-27483 Factor VIIa Inhibitor

The Company�� Factor VIIa inhibitor PCI-27483 is a first-in-human small molecule inhibitor that selectively targets FVIIa. As an inhibitor of FVIIa, PCI-27483 has two potential mechanisms of action: inhibition of intracellular signaling involved in tumor growth and metastases and inhibition of early coagulation processes associated with thromboembolism.

Factor VIIa PCI-27483 Clinical Development Update

A multicenter Phase I/II of PCI-27483 in patients with locally a! dvanced o! r metastatic pancreatic cancer that are either receiving or are planned to receive gemcitabine therapy has completed enrollment. The Phase II portion of the study randomized patients to receive either gemcitabine alone or gemcitabine plus PCI-27483 (1.2 mg/kg twice daily). The objectives are to assess the safety of FVIIa Inhibitor PCI-27483 at pharmacologically active dose levels, to assess potential inhibition of tumor progression and to obtain initial information of the effects on the incidence of thromboembolic events. Due to a paradigm shift away from the use of gemcitabine alone for the treatment of pancreatic cancer, enrolling patients in this randomized study has been challenging. PCYC is evaluating other alternatives for development of this agent.

A multicenter Phase I/II of PCI-27483 in patients with locally advanced or metastatic pancreatic cancer that are either receiving or are planned to receive gemcitabine therapy has completed enrollment. The Phase II portion of the study randomized patients to receive either gemcitabine alone or gemcitabine plus PCI-27483 (1.2 mg/kg twice daily). PCI-27483 is covered by United States patents and patent applications and counterpart patents and patent applications in fourteen ex-United States territories, including Europe, Canada, Mexico, Japan, China, India, South Korea, Australia and Brazil.

Advisors' Opinion:

• [By Anders Bylund]

  And then there's cancer drug developer Pharmacyclics (NASDAQ: PCYC  ) . This stock had been trading like a roller coaster when the poison pill quietly got the kibosh, and continued to trade sideways for another couple of years. Then Pharmacyclics' cancer treatments made some headway in FDA proceedings led by leukemia drug Ibrutinib, sending the stock on a rocket ride. Pharmacyclics' returns of 2,500% since the plan change make the S&P 500's 45% jump look like dead money. And Pharmacyclics may work together with some big partners, but remains a separate business to this day.

• [By Jay Silverman]

  Over the past year, including the end of this year, we've had new blockbuster drugs for hepatitis C, which is Gilead's (GILD) drug, and also for B-cell lymphomas, which is Pharmacyclics' (PCYC) drug. Those are looking to be two of the biggest drugs ever.

• [By Sean Williams]

  The other factor that makes J&J a company I wouldn't dare bet against is its top-notch pharmaceutical program. J&J has delivered incredible wins over the past couple of quarters including the approval of Invokana, the first SGLT-2 inhibitor approved in the U.S. to treat Type 2 diabetes, as well as its December 2011 licensing partnership with Pharmacyclics (NASDAQ: PCYC  ) over experimental drug, ibrutinib, which has been designated as a breakthrough therapy by the Food and Drug Administration for the treatment of two rare blood cancers and could generate up to $5 billion in peak sales if approved (it's currently under review by the FDA).

Top Japanese Companies To Buy Right Now: Iberdrola SA (IBE)

Iberdrola SA is a Spain-based company principally engaged in the energy sector. The Company's business is structured in four segments: Network Business, including all the energy transmission and distribution activities, and any other regulated activity originated in Spain, the United Kingdom, the United States and Brazil; Deregulated Business, including electricity generation and sales businesses as well as gas trading and storage businesses carried on by the Group in Spain, Portugal, the United Kingdom and North America; Renewable: activities relating to renewable energies in Spain, the United Kingdom, the United States and the rest of the world; Other Businesses, comprising the engineering and construction businesses and the non-power businesses; and Corporation which includes the costs of the Group's structure (Single Corporation), of the administration services of the corporate areas that are subsequently invoiced to the other companies through either specific service. Advisors' Opinion:

• [By Sarah Jones]

  Iberdrola SA (IBE), Spain�� biggest power company, fell 3.4 percent to 3.87 euros. Endesa SA (ELE) slumped 4.6 percent to 16 euros, while Acciona SA (ANA), which owns more than 4 gigawatts of wind farms in the country, tumbled 8.5 percent to 37.95 euros. Red Electrica Corp. slid 7.5 percent to 38.34 euros.

Top Japanese Companies To Buy Right Now: Ishares Trust Dow Jones United States (IDU)

iShares Dow Jones U.S. Utilities Sector Index Fund (the Fund) seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Utilities Index (the Index). The Index measures the performance of the utilities sector of the United States equity market. The Index includes companies in industry groups, such as electricity and gas, water and multi-utilities. The Index is a subset of the Dow Jones U.S. Total Market Index and is capitalization weighted. The Index is reconstituted quarterly.

The Fund will concentrate its investments in a particular industry or group of industries to approximately the same extent as the Index is so concentrated. The Fund�� investment advisor is Barclays Global Fund Advisors.

Advisors' Opinion:

• [By Richard Stavros]

  In early August, Vanguard Utilities ETF (NYSE: VPU), iShares US Utilities (NYSE: IDU), and Fidelity MSCI Utilities Index ETF (NYSE: FUTY) added almost $250 million in new assets combined, more than enough to offset outflows from Utilities Select Sector SPDR Fund (NSDQ: XLU).

Top Japanese Companies To Buy Right Now: ICICI Bank Ltd (IBN)

ICICI Bank Limited (the Bank), incorporated on January 5, 1994, is a banking company. The Bank, together with its subsidiaries, joint ventures and associates, is a diversified financial services group providing a range of banking and financial services, including commercial banking, retail banking, project and corporate finance, working capital finance, insurance, venture capital and private equity, investment banking, broking and treasury products and services. It operates under four segments: retail banking, wholesale banking, treasury and other banking. Retail Banking includes exposures of the Bank, which satisfy the four criteria of orientation, product, granularity and low value of individual exposures for retail exposures. Wholesale Banking includes all advances to trusts, partnership firms, companies and statutory bodies, which are not included under Retail Banking. Treasury includes the entire investment portfolio of the Bank. Other Banking includes hire purchase and leasing operations and other items. As of March 31, 2012, the Bank had 17 subsidiaries. During the fiscal year ended March 31, 2013, the Company added 348 branches and 1,475 automated teller machines (ATMs) to its network, taking its branch and ATM count to 3,100 and 10,481 respectively at March 31, 2013.

Retail Banking

The branch network serves as an integrated channel for deposit mobilization, selected retail asset origination and distribution of third-party products, as well as the focal point for customer service. During fiscal 2011, the Bank continued its focus on increasing the proportion of low-cost retail deposits in its funding base. During fiscal 2011, its retail disbursements increased as it focused on opportunities in residential mortgages, vehicle finance and construction equipment finance. The Company also continued to focus on cross-selling new products and products of its life and general insurance subsidiaries to its existing customers. As of March 31, 2013, its ATMs offer services such a! s opening fixed deposits, payment of credit card and utility bills, payment of insurance premium, mobile re-charges and ultra fast cash.

Small Enterprises

The Company offers banking solutions to small and medium enterprises across industry segments. The Company supports the growth of the small and medium enterprises sector while adopting a cluster-based financing approach for enterprises with a homogeneous profile in industries, such as infrastructure, engineering, information technology, education, life-sciences and agri-based businesses. The Company also offers supply chain financing solutions to the channel partners of large corporates.

Corporate Banking

The Bank offers a suite of corporate banking products, including rupee and foreign currency debt, working capital credit, structured financing, loan syndication and commercial banking products and services. The Company also puts in place product specific teams with a view to focus on designing financial solutions for clients spread across structured finance, project finance, loan syndication and markets. The relationship team also works with its Markets Group to assist customers in devising and executing risk management strategies to address foreign currency, interest rate and liquidity risks. Its loan syndication franchise enables the Bank to structure, underwrite and syndicate rupee and foreign currency debt with Indian and offshore investors. The Bank has built robust sector-specific syndication skills across project finance, merger and acquisition (M&A) financing and structured finance to provide optimal financing solutions.

International Banking

The Company�� international banking business is focused on meeting the foreign currency needs of its Indian corporate clients and partnering them in their global expansion, taking select trade finance exposures linked to imports to India. ICICI Bank has subsidiaries in the United Kingdom, Russia and Canada, branches in the U! nited Sta! tes, Singapore, Bahrain, Hong Kong, Sri Lanka, Dubai International Finance Centre and Qatar Financial Centre and representative offices in the United Arab Emirates, China, South Africa, Bangladesh, Thailand, Malaysia and Indonesia. The Bank�� wholly owned subsidiary, ICICI Bank UK PLC, has 11 branches in the United Kingdom and a branch each in Belgium and Germany. ICICI Bank Canada has nine branches. ICICI Bank Eurasia Limited Liability Company has one branch.

The Company develops products and service offerings to meet the requirements of the Non Resident Indian (NRI) community. The Bank launched I-Express, an instant cross-border money transfer option for NRIs through its select partners in the Middle East. The I-Express facility offers the remitter an option of visiting any partner outlet for instant credit into the beneficiary account maintained with ICICI Bank in India, at no extra cost. The Company also launched Fixed Rupee on Money2India.com, a facility that enables NRIs to send the exact rupee amount remittance to India since the exchange rate is confirmed at the time of initiating the remittance.

Inclusive and Rural Banking

Inclusive and Rural Banking include offering credit to the rural market through the Bank's branches and dedicated field teams and financial inclusion through business correspondents. The Bank focuses on improving its product and service offerings to meet the requirements of all participants in the rural market, including farmers, traders, commission agents, small processors and other medium agri-corporates. The Bank focuses on building capacity to implement its financial inclusion plan. The Bank also focused on opening accounts for routing benefit payments under various government schemes and has received the mandate for opening accounts of individuals under these schemes in certain states.

The Bank has also identified 25 business correspondents having a network of over 7,500 customer service points, to service these cust! omers. Th! e Bank provides basic financial services to the unbanked and underbanked

population comprising small and marginal farmers, daily wage labourers, beneficiaries of government. Around 47% of the Bank�� branches are in rural and semi-urban areas

Treasury

The Bank provides provide foreign exchange and derivative products and services to customers through its Markets Group. These products and services include foreign exchange products for hedging currency risk, foreign exchange and interest rate derivatives, such as options and swaps and bullion transactions.

Advisors' Opinion:

• [By Chuck Carnevale]

  ICICI Bank Limited-ADR (IBN)

  My second featured aggressive financial is ICICI Bank Limited-ADR (IBN), an ADR (American Depository Receipt) headquartered in India. This company is the largest private sector bank in India. Current low valuation is what most attracted me to this aggressive selection. However, I believe that prospective investors should carefully consider the amount of price volatility that has historically occurred with their share price. Nevertheless, for those dividend growth investors with a stomach for risk, this company may be worth taking a closer look at.

• [By Selena Maranjian]

  Finally, Caxton Associates' biggest closed positions included Sprint Nextel�and JPMorgan Chase. Other closed positions of interest include India-based ICICI Bank (NYSE: IBN  ) . In April, the bank reported double-digit profit increases and rising ROE. Analysts at Zacks downgraded the bank earlier this month, though, citing deterioration of its credit quality and expected steep operating expenses.

• [By Anuchit Nguyen]

  Indian stocks declined, with the benchmark index halting a four-week rally, after central bank Governor Raghuram Rajan�� comment that inflation is still high. ICICI Bank (IBN) dropped to the lowest level since Sept. 5. The S&P BSE Bankex Index retreated 1.8 percent.

• [By Selena Maranjian]

  Finally, Viking's biggest closed positions included News Corp.�and Schlumberger. Other closed positions of interest include India-based ICICI Bank (NYSE: IBN  ) . In April, the bank reported double-digit profit increases and rising ROE, and it recently yielded 2%. Analysts at Zacks downgraded the bank earlier this month, though, citing deterioration of its credit quality and expected steep operating expenses. ICICI is a major lender in India and is growing briskly there, and is�expanding abroad, targeting even China. Its stock is up about 29% over the past year and has averaged 20.5% annually over the past decade.